




RealRate

PHARMACEUTICAL 2024

Johnson Johnson
Rank 117 of 309

Johnson & Johnson



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Johnson Johnson are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Johnson Johnson compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Johnson Johnson is the variable Assets, Current, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 259%, being 45% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	53,495,000
Cost of Goods Sold	26,553,000
Intangible Assets	70,733,000
Liabilities, Current	46,282,000
Liabilities, Non-Current	39,279,000
Other Assets	23,432,000
Other Compr. Net Income	-4,741,000
Other Expenses	3,310,000
Other Liabilities	13,223,000
Other Net Income	16,454,000
Other Revenues	85,159,000
Property and Equipment	19,898,000
Research and Development	15,085,000
Selling, General and Administrative Expense	21,512,000

Output Variable	Value in 1000 USD
Assets	167,558,000
Liabilities	98,784,000
Expenses	66,460,000
Revenues	85,159,000
Stockholders Equity	68,774,000
Net Income	35,153,000
Comprehensive Net Income	32,782,500
BaseVar	219,578,000
ECR before Limited Liability	137%
Economic Capital Ratio	259%